.png)
Nocteva
Organoid models and drug discovery services for rare disease researchers and biotech companies
Highlights
- Young companyFounded 2025
- New on EvolcAdded 2026-10-28
About Nocteva
Nocteva develops human organoid models from patient-derived cells for disease research, drug discovery and personalized medicine, with a focus on inherited rare diseases. Its services include disease modeling, drug screening, molecular profiling and bioinformatics.
It works with research groups, hospitals, biotech companies and technology providers in Norway and abroad. It also sells cell culture media and laboratory solutions used in organoid workflows.
Founded in 2025, Nocteva is headquartered in Trondheim, Norway. It allocates a share of its commercial surplus to a research reserve supporting rare disease research and platform development.
Product: Patient-derived organoid models, translational research services, cell culture media and laboratory solutions.
Jobs at Nocteva
Leadership
- Magnar Bjørås · CEO & Co-FounderSource: company website
More biotech & pharma companies
Norsk Medisinsk Syklotronsenter
Makes short-lived PET radiopharmaceuticals for diagnostic imaging, serving clinics and pharma partners from OsloNew on EvolcNuclithera
Targeted radiopharmaceuticals for patients with metastatic and difficult-to-treat cancersYoung companyNew on EvolcNykode Therapeutics
Develops immunotherapies for patients with cancer and autoimmune diseases using a modular biotech platformNew on EvolcOncosyne
Tumoroid-based drug screening and predictive diagnostics for pharmaceutical companies and cancer care providersNew on EvolcPharma Holdings
Develops intranasal antimicrobial drugs for patients with respiratory viral infectionsNew on EvolcPluvia
Develops small-molecule drugs for patients with rare protein-misfolding disorders, starting with phenylketonuria (PKU)New on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- AWS
- Cloudflare
- Webflow